🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

41 results for “Tour” Clear

  1. Raludotatug Deruxtecan

    Daiichi Sankyo Europe GmbH

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  2. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  4. VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)

    Tour Hekla

    patients with stable coronary artery disease

    phase 2 small molecule active

    1 trial

  5. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule completed

    4 trials

  6. Xarelto 2.5 mg film-coated tablets

    Tour Hekla

    Chronic hemodialysis

    phase 2 small molecule active

    1 trial

  7. Yigansan

    China SXT Pharmaceuticals

    Tourette Disorder

    phase 2 small molecule completed

    1 trial

  8. pimozide

    Ultragenyx UK Limited

    Tourette Syndrome

    phase 2 small molecule completed

    1 trial

  9. risperidone

    Ultragenyx UK Limited

    Tourette Syndrome

    phase 2 small molecule completed

    1 trial

  10. Replens and coconut oil

    Summit Therapeutics

    Genitourinary Abnormality

    phase 1 other terminated

    1 trial

  11. SD-809

    Teva Pharma GmbH

    TOURETTE SYNDROME

    phase 1 small molecule completed

    1 trial

  12. CHLORURE DE SODIUM 0,9 % VIAFLO, solution pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Tour Hekla

    1st line treatment for unresectable metastatic colorectal cancer

    approved small molecule active

    1 trial

  13. Carvedilol NORMON 6.25 mg tablets EFG., Il n'a pas de substance active. Le produit est un comprimé pelliculé sécable blanc, de forme ovale, de longueur 8mm, avec une gravure F57 sur une face et une barre de sécabilité sur l’autre face. Excipients: Prosolv Easytab SP (Cellulose microcristalline, Silice colloïdale, Sodium starch glycolate, Sodium stéaryl fumarate). Solution de pelliculage: (Hypromellose, PEG 3350, Candurin silver sheen)

    Tour Hekla

    Asymptomatic Child-Pugh A5 to B8 cirrhosis

    approved small molecule active

    1 trial

  14. Cellular Matrix / A-CP-HA Kit

    Regeneron Ireland Designated Activity Company (DAC)

    Genitourinary Syndrome of Menopause

    approved small molecule active

    1 trial

  15. Iohexol 300 mg I/ml solution for injection, MORPHINE (CHLORHYDRATE) RENAUDIN 1 mg/ml, solution injectable

    Tour Hekla

    Evaluation of the CKD-Epi score to identify a glomerular filtration threshold predictive of morphine failure at usual dosage, using a reference method for assessing renal function: iohexol clearance. All other aspects of the protocol are part of standard care practice.

    approved small molecule active

    1 trial

  16. PROPESS 10 mg, système de diffusion vaginal, PROSTINE E2 2 mg/3 g, gel vaginal, ANGUSTA 25 microgrammes, comprime, OXYTOCINE PANPHARMA 5 UI/1 ml, solution injectable

    Tour Hekla

    Labor Induction of women with an unfavorable Cervix after 24 hours of cervical ripening

    approved small molecule active

    1 trial

  17. RITALINE L.P. 10 mg, gélule à libération prolongée

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources